Soluble CD163 levels are elevated in cerebrospinal fluid and serum in people with Type 2 diabetes mellitus and are associated with impaired peripheral nerve function

Diabetic Medicine

Volumn 32, Issue 1, 2015, Pages 54-61

  Kallestrup, M ^a   Moller H J ^a   Tankisi, H ^a   Andersen, H ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CD163 ANTIGEN; SOLUBLE CD163 ANTIGEN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DIABETIC NEUROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; NERVE CONDUCTION; NERVE FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCEPTIVE THRESHOLD; PERIPHERAL NERVE; VIBRATION SENSE; BLOOD; BODY MASS; COMPARATIVE STUDY; INFLAMMATION; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOLOGICAL MARKERS; BODY MASS INDEX; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NEURAL CONDUCTION; RECEPTORS, CELL SURFACE;

EID: 84916620102     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12568     Document Type: Article

References (30)

1. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33: 2285-2293.
2. Herder C, Bongaerts BW, Rathmann W, Heier M, Kowall B, Koenig W et al. Association of Subclinical Inflammation With Polyneuropathy in the Older Population: KORA F4 study. Diabetes Care 2013; 36: 3663-3670.
3. Doupis J, Lyons TE, Wu S, Gnardellis C, Dinh T, Veves A. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J Clin Endocrinol Metab 2009; 94: 2157-2163.
4. Shi X, Chen Y, Nadeem L, Xu G. Beneficial effect of TNF-alpha inhibition on diabetic peripheral neuropathy. J Neuroinflammation 2013; 10: 69.
5. Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol 2011; 7: 573-583.
6. Herder C, Lankisch M, Ziegler D, Rathmann W, Koenig W, Illig T et al. Subclinical inflammation and diabetic polyneuropathy: MONICA/KORA Survey F3 (Augsburg, Germany). Diabetes Care 2009; 32: 680-682.
7. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK et al. Identification of the haemoglobin scavenger receptor. Nature 2001; 409: 198-201.
8. Moller HJ. Soluble CD163. Scand J Clin Lab Invest 2012; 72: 1-13.
9. Etzerodt A, Moestrup SK. CD163 and inflammation: biological, diagnostic, and therapeutic aspects. Antioxid Redox Signal 2013; 18: 2352-2363.
10. Moller HJ, Frikke-Schmidt R, Moestrup SK, Nordestgaard BG, Tybjaerg-Hansen A. Serum soluble CD163 predicts risk of type 2 diabetes in the general population. Clin Chem 2011; 57: 291-297.
11. Galea I, Felton LM, Waters S, van Rooijen N, Perry VH, Newman TA. Immune-to-brain signalling: the role of cerebral CD163-positive macrophages. Neurosci Lett 2008; 448: 41-46.
12. Satoh J, Yagihashi S, Toyota T. The possible role of tumor necrosis factor-alpha in diabetic polyneuropathy. Exp Diabesity Res 2003; 4: 65-71.
13. Dyck PJ, Kratz KM, Lehman KA, Karnes JL, Melton LJ, 3rd, O'Brien PC et al. The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology 1991; 41: 799-807.
14. Dyck P. Quantitating severity of neuropathy. In: Dyck P, Thomas P, Griffin J, Low P, Poduslo J eds. Peripheral neuropathy. Philadelphia: WB Saunders, 1993: 686-97.
15. Dyck PJ, Sherman WR, Hallcher LM, Service FJ, O'Brien PC, Grina LA et al. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol 1980; 8: 590-596.
16. Moller HJ, Hald K, Moestrup SK. Characterization of an enzyme-linked immunosorbent assay for soluble CD163. Scand J Clin Lab Invest 2002; 62: 293-299.
17. Conti G, Scarpini E, Baron P, Livraghi S, Tiriticco M, Bianchi R et al. Macrophage infiltration and death in the nerve during the early phases of experimental diabetic neuropathy: a process concomitant with endoneurial induction of IL-1beta and p75NTR. J Neurol Sci 2002; 195: 35-40.
18. Younger DS. Diabetic neuropathy: a clinical and neuropathological study of 107 patients. Neurol Res Int 2010; 2010: 140379.
19. Vargas R, Rincon J, Pedreanez A, Viera N, Hernandez-Fonseca JP, Pena C et al. Role of angiotensin II in the brain inflammatory events during experimental diabetes in rats. Brain Res 2012; 1453: 64-76.
20. Galea J, Cruickshank G, Teeling JL, Boche D, Garland P, Perry VH et al. The intrathecal CD163-haptoglobin-hemoglobin scavenging system in subarachnoid hemorrhage. J Neurochem 2012; 121: 785-792.
21. Parkner T, Sorensen LP, Nielsen AR, Fischer CP, Bibby BM, Nielsen S et al. Soluble CD163: a biomarker linking macrophages and insulin resistance. Diabetologia 2012; 55: 1856-1862.
22. Zanni MV, Burdo TH, Makimura H, Williams KC, Grinspoon SK. Relationship between monocyte/macrophage activation marker soluble CD163 and insulin resistance in obese and normal-weight subjects. Clin Endocrinol 2012; 77: 385-390.
23. Hogan AE, Gaoatswe G, Lynch L, Corrigan MA, Woods C, O'Connell J et al. Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetologia 2014; 57: 781-784.
24. Espinoza-Jimenez A, Peon AN, Terrazas LI. Alternatively activated macrophages in types 1 and 2 diabetes. Mediators Inflamm 2012; 2012: 815953.
25. Ludwig J, Binder A, Steinmann J, Wasner G, Baron R. Cytokine expression in serum and cerebrospinal fluid in non-inflammatory polyneuropathies. J Neurol Neurosurg Psychiatry 2008; 79: 1268-1273.
26. Shi X, Chen Y, Nadeem L, Xu G. Beneficial effect of TNF-alpha inhibition on diabetic peripheral neuropathy. J Neuroinflammation 2013; 10: 69.
27. Skundric DS, Lisak RP. Role of neuropoietic cytokines in development and progression of diabetic polyneuropathy: from glucose metabolism to neurodegeneration. Exp Diabesity Res 2003; 4: 303-312.
28. Horton AR, Barlett PF, Pennica D, Davies AM. Cytokines promote the survival of mouse cranial sensory neurones at different developmental stages. Eur J Neurosci 1998; 10: 673-679.
29. Gundogdu BM. Diabetic peripheral neuropathy: an update on pathogenesis and management. Curr Neurol Neurosci Rep 2006; 6: 1-4.
30. Purwata TE. High TNF-alpha plasma levels and macrophages iNOS and TNF-alpha expression as risk factors for painful diabetic neuropathy. J Pain Res 2011; 4: 169-175.